PDCD1 and neoplasm: The ASPIRE system codelivered CD80/86 with an anti-PD-1 antibody, achieving effective reversal of tumour immune suppression and promoting functional remodelling of exhausted T cells in Lewis lung carcinoma (LLC) models and MC-38 colon carcinoma models [211].